Nucleic Acid Medicine Market Research Report
On Oct 28, Global Info Research released "Global Nucleic Acid Medicine Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031". This report includes an overview of the development of the Nucleic Acid Medicine industry chain, the market status of Nucleic Acid Medicine Market, and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Nucleic Acid Medicine.
According to our latest research, the global Nucleic Acid Medicine market size will reach USD 22137 million in 2031, growing at a CAGR of 7.3% over the analysis period.
Nucleic Acid Medicine refers to a new class of molecular therapeutics that utilize DNA, RNA, or their derivatives as active agents to achieve therapeutic effects by regulating gene expression, modifying genetic information, or influencing protein synthesis. Unlike traditional small-molecule or protein-based drugs, nucleic acid medicines intervene directly at the genetic level, offering high specificity, rapid development cycles, and broad therapeutic potential. Major categories include antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA) drugs, riboswitches, aptamers, and CRISPR-based gene editing therapies. With continuous progress in delivery systems, chemical modification, and manufacturing technologies, nucleic acid medicine is rapidly advancing toward commercialization and has become a key innovation driver in precision medicine, rare disease treatment, vaccine development, and cancer immunotherapy.The average gross profit margin for this product is 85%.
The global nucleic acid medicine market is entering a stage of structural growth. With the deepening concept of precision medicine and regulatory relaxation for gene therapies, nucleic acid drugs are widely recognized as the next-generation therapeutic platform. Governments across major markets are strengthening support for RNA and gene drug innovation, while strategic alliances between large pharmaceutical firms and emerging biotech companies accelerate commercialization. The success of mRNA vaccines has validated the feasibility of nucleic acid-based drugs, spurring extensive R&D and investment in mRNA, siRNA, and ASO therapies across infectious diseases, oncology, and rare disorders, thereby boosting market confidence.
Despite promising prospects, nucleic acid medicines face key technical and regulatory barriers, including limited delivery efficiency, in vivo instability, and immunogenicity concerns. Complex manufacturing processes and stringent quality standards drive up production costs and hinder scalability. In addition, certain regulatory frameworks are still evolving regarding long-term safety, traceability, and ethical governance, resulting in lengthy clinical translation cycles and high approval uncertainty. Financial market pressure for near-term returns also constrains R&D investment and pipeline expansion.
Downstream demand is primarily driven by rare disease therapy, cancer immunotherapy, and personalized vaccines. Hospitals and research institutes are accelerating nucleic acid drug applications in genetic, metabolic, cardiovascular, and neurological disorders. With the programmable nature of RNA platforms becoming increasingly validated, pharmaceutical companies are building rapid “target-to-therapy” development models, fueling demand for customized nucleic acid products. Moreover, as mRNA technology extends beyond human health, new opportunities are emerging in veterinary vaccines, agriculture, and aesthetic medicine.
The upstream segment of the nucleic acid medicine industry encompasses nucleotide raw materials, synthetic enzymes, lipid nanoparticles (LNPs), and chemical modification reagents. Supply capability for high-purity oligonucleotides and specialized enzymes is critical for industry competitiveness. In recent years, several Western and Asian manufacturers have established GMP-grade production systems to achieve vertical integration. Chinese enterprises are making notable advances in enzyme engineering, nucleic acid modification chemistry, and nanodelivery technologies, reshaping the global supply landscape. The ongoing localization of raw material technologies provides strategic advantages for cost control and supply chain resilience.
This report is a detailed and comprehensive analysis for global Nucleic Acid Medicine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Sample Report Request Nucleic Acid Medicine
https://www.globalinforesearch.com/reports/3063251/nucleic-acid-medicine
Market segment by Type: Antisense Oligonucleotides (ASO)、 siRNA、 mRNA、 Other
Market segment by Application: Neuromuscular Diseases、 hATTR、 COVID-19、 Other
Major players covered: Sarepta Therapeutics、 Ionis Pharmaceuticals、 Alnylam、 Biogen、 Nippon Shinyaku、 Sobi、 Novartis、 BioNTech、 Pfizer、 Moderna Therapeutics、 Jazz Pharmaceuticals、 Novo Nordisk、 AstraZeneca、 Astellas Pharma
Market segment by region, regional analysis covers: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia),South America (Brazil, Argentina, Colombia, and Rest of South America),Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa).
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Nucleic Acid Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Nucleic Acid Medicine, with price, sales, revenue and global market share of Nucleic Acid Medicine from 2020 to 2025.
Chapter 3, the Nucleic Acid Medicine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Nucleic Acid Medicine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2020 to 2024.and Nucleic Acid Medicine market forecast, by regions, type and application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Nucleic Acid Medicine.
Chapter 14 and 15, to describe Nucleic Acid Medicine sales channel, distributors, customers, research findings and conclusion.
Data Sources:
Via authorized organizations:customs statistics, industrial associations, relevant international societies, and academic publications etc.
Via trusted Internet sources.Such as industry news, publications on this industry, annual reports of public companies, Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), Trading Economics, News Network, Statista, Federal Reserve Economic Data, BIS Statistics, ICIS, Companies House Documentsm, investor presentations, SEC filings of companies, etc.
Via interviews. Our interviewees includes manufacturers, related companies, industry experts, distributors, business (sales) staff, directors, CEO, marketing executives, executives from related industries/organizations, customers and raw material suppliers to obtain the latest information on the primary market;
Via data exchange. We have been consulting in this industry for 16 years and have collaborations with the players in this field. Thus, we get access to (part of) their unpublished data, by exchanging with them the data we have.
Via our long-term tracking and gathering of data from this industry.We have a database that contains history data regarding the market.
About Us:
Global Info Research
Web: https://www.globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
US: 001-347 966 1888
Email: report@globalinforesearch.com
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
